Identifying a protein that plays a key role in cancer cell growth is a first step toward the development of a targeted cancer therapy. It is especially promising when this protein is dispensable for the growth of normal cells. Their discovery that UNC45A fits these criteria has researchers, led by Dr. Ahmed Chadli, of the Georgia Cancer Center at Augusta University, excited about potential new cancer therapeutic strategies involving the inhibition of UNC45A.